p27 Kip1 is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27 Kip1 protein expression in normal and benign prostatic epithelia as well as the possible
Dynamic changes in p27kip1 variant expression in activated lymphocytes
✍ Scribed by B. Yaroslavskiy; S.C. Watkins; Sean Alber; Richard A. Steinman
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 317 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0730-2312
- DOI
- 10.1002/jcb.1243
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The p27Kip1 cell cycle inhibitor (p27) has emerged as a critical mediator of normal cellular growth control. We report the expression of a 24 kD C‐terminal variant of p27 in normal peripheral blood lymphocytes. This variant is rapidly degraded in a proteasome‐dependent manner when lymphocytes are activated by interleukin‐2 or by superantigen. Whereas p24 degradation is complete within 16 h of mitogen addition, full‐length p27 is decreased only modestly over 72 h of mitogen exposure and is present in activated and cycling lymphocytes. Persistent p27 is present in a complex with cyclin D3 in activated lymphocytes, and is localized both in the nucleus and cytoplasm. These results indicate that lymphocytes exiting from quiescence use several mechanisms to overcome the p27Kip1‐enforced cell cycle checkpoint, and that elimination of p27 is not required for cell cycle entry. J. Cell. Biochem. 83: 380–389, 2001. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Livers from wild‐type and p53‐deficient mice were analyzed for the expression of cell‐cycle regulatory proteins in an attempt to determine the mechanism for the increased proliferation of liver cells in p53‐deficient mice associated with enhanced susceptibility to aflatoxin‐induced live
This study has evaluated the expression of the cyclin-dependent kinase inhibitor p27 Kip1 in 89 colorectal cancers (CRCs) using immunohistochemistry and has related p27 levels to clinico-pathological characteristics, tumour cell proliferation, and the expression of other G1-S transition regulatory p
## Abstract ## Background p27^Kip1^, a cyclin‐dependent kinase inhibitor, negatively regulates the G1 phase progression of the cell cycle by binding to the cyclin E/cyclin‐dependent kinase 2 complex. This study was done to investigate the expression of p27^Kip1^ in mucoepidermoid carcinomas and it
Oligodendrocyte differentiation is a ble for G1/S transition, as immunodepletion of oligocomplex process believed to be controlled by an intrindendrocyte extracts of p27 protein resulted in the actisic mechanism associated with cell-cycle arrest. Revation of CDK2 activity. However, cells that became